

Mouse Anti-SLFN11/Schlafen 11 [E4]: MC0480, MC0480RTU7

Intended Use: For Research Use Only

Description: Schlafen (SLFN) family members are preferentially expressed in lymphoid tissues and are differentially regulated during thymocyte maturation. Schlafen proteins function as suppressors of cell growth and are thought to play a role in the maintenance of T cell quiescence. All members of the Schlafen family contain a conserved core domain and are substantially diversified at the N terminus. Changes in Schlafen protein expression may contribute to phenotypic differences seen in thymic subsets. SLFN11 (also known as SLFN8/9) is a nuclear protein that belongs to the Schlafen family of genes involved in cell cycle regulation and growth inhibition. Expression of SLFN11 predicts sensitivity of cancer cell lines to DNA-damaging agents. Evidence suggests that in the presence of DNA-targeted therapies, SLFN11 is recruited to stressed replication forks where it blocks replication, leading to cell death. SLFN11 is being explored as a predictive biomarker for response to DNA-targeted therapies.

Specifications:


Clone:	E4
Source:	Mouse
Isotype:	IgG1k
Reactivity:	Human
Immunogen:	Epitope aa 733-765 of the human SLFN11 C-terminus
Localization:	Nucleus, some cytoplasm
Formulation:	Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN ₃)
Storage:	Store at 2°- 8°C
Applications:	IHC, ELISA, IF, IP, WB
Package:	

Description	Catalog No.	Size
SLFN11/Schlafen 11 [E4] Concentrated	MC0480	1 ml
SLFN11/Schlafen 11 [E4] Prediluted	MC0480RTU7	7 ml

IHC Procedure*:

Positive Control Tissue:	Colon, colon carcinoma, breast carcinoma
Concentrated Dilution:	50-200
Pretreatment:	Tris EDTA pH9.0 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human lung tissue stained with anti-SLFN11 using DAB

References:

1. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors. Sai-Wen Tang, et al. Clin Cancer Res. Apr 15;24(8):1944-1953, 2018. doi: 10.1158/1078-0432.CCR-17-0443.
2. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Kelli L Goss, et al. Oncotarget. Sep 27;7(39):63003-63019, 2016. doi: 10.18632/oncotarget.11416.